Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Assets (2018 - 2025)

X4 Pharmaceuticals' Assets history spans 8 years, with the latest figure at $290.5 million for Q4 2025.

  • For Q4 2025, Assets rose 98.34% year-over-year to $290.5 million; the TTM value through Dec 2025 reached $290.5 million, up 98.34%, while the annual FY2025 figure was $290.5 million, 98.34% up from the prior year.
  • Assets reached $290.5 million in Q4 2025 per XFOR's latest filing, up from $163.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $290.5 million in Q4 2025 to a low of $81.0 million in Q2 2022.
  • Average Assets over 5 years is $147.2 million, with a median of $144.1 million recorded in 2021.
  • Peak YoY movement for Assets: soared 114.02% in 2023, then plummeted 50.07% in 2025.
  • A 5-year view of Assets shows it stood at $117.2 million in 2021, then surged by 32.78% to $155.6 million in 2022, then fell by 5.35% to $147.3 million in 2023, then fell by 0.55% to $146.4 million in 2024, then soared by 98.34% to $290.5 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Assets are $290.5 million (Q4 2025), $163.6 million (Q3 2025), and $105.2 million (Q2 2025).